225PPredictors of adherence among post-menopausal women receiving adjuvant endocrine therapy for breast cancer in Ontario, Canada
ConclusionsNon-adherence to endocrine therapy appears to be more common among older breast cancer patients. Short-term follow-up visit by a patient ’s medical oncologist after starting AET may help to improve adherence. Developing strategies to optimize endocrine therapy adherence are warranted.Legal entity responsible for the studyThe authors.FundingAcademic Medical Association of South Western Ontario (AMOSO).DisclosureT. Vandenberg: Advisory / Consultancy: Novartis; Advisory / Consultancy: Roche. K. Pritchard: Advisory / Consultancy: Pfizer; Advisory / Consultancy: Roche; Advisory / Consultancy: Amgen; Advisory / Consultancy: Novartis; Advisory / Consultancy: Eisai; Advisory / Consultancy: Genomic Health; Advisory / Consultancy: Myriad Genetics. A. Louie: Advisory / Consultancy: AstraZeneca; Honoraria (self): Varian Medical Systems Inc. J. Raphael: Honoraria (self): Hoffmann La Roche. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: AstraZeneca | Breast Cancer | Breast Lumpectomy | Canada Health | Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Endocrine Therapy | Genetics | Hormones | Legislation | Lumpectomy | Mastectomy | Men | Menopause | Pfizer | Tamoxifen | Women